422 results match your criteria: "Shenzhen Blood Center[Affiliation]"

[Study on the Relationship between the Level of Soluble HLA-E Molecules in Plasma and Gene Polymorphism and Leukemia].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

April 2022

Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen 518035, Guangdong Province, China,E-mail:

Objective: To explore the relationship between the level of soluble HLA-E (sHLA-E) molecules in plasma and gene polymorphism and leukemia in Shenzhen of China.

Methods: Enzyme-linked immunosorbent assay was used to detect sHLA-E level in plasma of 103 leukemia patients and 113 healthy blood donors. PCR-SBT was used to identify the HLA-E genotype of 73 leukemia patients and 76 healthy blood donors.

View Article and Find Full Text PDF

Establishment of Rapid Detection Methods for rs76971248 Related to Leukemia.

Dis Markers

April 2022

Institution of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong 518035, China.

Background: The HLA-E gene is a member of the HLA-I gene family. Its genetic polymorphism is regarded as associated with numerous diseases. Establishing a rapid and accurate detection method of disease-related SNP sites in HLA-E is particularly important.

View Article and Find Full Text PDF

The HLA-A*31:188N allele differs from A*31:01:02:01 by a single nucleotide deletion in exon 3.

View Article and Find Full Text PDF

Characterization of a novel variant allele, HLA-C*03:587, identified in a Chinese Han individual.

HLA

July 2022

Immunogenetics Laboratory, Shenzhen Institution of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, China.

Article Synopsis
  • - The novel HLA-C*03:587 allele has a specific genetic variation compared to the closely related C*03:03:01:01 allele.
  • - This difference specifically occurs in exon 5 of the gene, which may affect its function or expression.
  • - Understanding these differences is important for studies related to genetics, immunology, and disease susceptibility.
View Article and Find Full Text PDF

Objective: To establish a based method flow cytometry to identify the antigen Jka in human red blood cells (RBCs) and verify its accuracy.

Methods: A total of 96 blood samples were enrolled in the study randomly from the voluntary blood donors in Shenzhen Blood Center. The RBCs were incubated with IgG anti-Jka primary antibody, and then labeled with the secondary antibody anti-IgG-Alexa Fluor 647.

View Article and Find Full Text PDF

Human leukocyte antigen (HLA)-E is one of the least polymorphic nonclassical major histocompatibility complex (MHC) I genes; its nucleotide variability can affect immune response. In this study, we assess the correlation between HLA-E polymorphism and leukemia and further study the transcriptional activity of promoter variation at nucleotide position-26. A total of 142 healthy blood donors and 111 leukemia patients were collected.

View Article and Find Full Text PDF

C*01:213 differs from C*01:02:01:01 by one nucleotide change at nucleotide 655 in exon 4 from T to G.

View Article and Find Full Text PDF

Discovery of the HLA-C*03:561 allele, a variant of HLA-C*03, in a Chinese individual.

HLA

February 2022

Immunogenetic Laboratory, Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China.

HLA-C*03:561 differs from HLA-C*03:02:02:01 by one nucleotide change in exon 4 at position 862 (G>A).

View Article and Find Full Text PDF

Background: Most Chinese Blood Centers adopted mini pool (MP) nucleic acid testing (NAT) for HBV screening due to high cost of Individual donation (ID) NAT, and different proportions of MP-reactive but ID-non-reactive donations (MP+/ID-, defined as non-resolved donations) have been observed during daily donor screening process. Some of these non-resolved donations are occult HBV infections (OBIs), which pose potential risk of HBV transmission if they are not deferred. This study is aimed to further analyze these non-resolved donations.

View Article and Find Full Text PDF

Identification of the novel HLA-DRB3*02:02:19 allele.

HLA

November 2021

HLA-DRB3, Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, China.

The HLA-DRB3*02:02:19 allele differs from DRB3*02:02:01:02 by a single nucleotide change in exon 2.

View Article and Find Full Text PDF

Identification of the novel HLA-C*15:192 allele that differs from HLA-C*15:02:01:01 at one position in exon 2.

View Article and Find Full Text PDF

A new RHD variant allele caused by an RHD c.1228-1G>C mutation in a Chinese family.

Transfusion

September 2021

Department of Blood Transfusion, The First Affiliated Hospital of Shenzhen University School of Medicine, The Second People's Hospital of Shenzhen, Shenzhen, China.

View Article and Find Full Text PDF

Single-molecule Förster resonance energy transfer (smFRET) is a powerful tool for investigating the dynamic properties of biomacromolecules. However, the success of protein smFRET relies on the precise and efficient labeling of two or more fluorophores on the protein of interest (POI), which has remained highly challenging, particularly for large membrane protein complexes. Here, we demonstrate the site-selective incorporation of a novel unnatural amino acid (2-amino-3-(4-hydroselenophenyl) propanoic acid, SeF) through genetic expansion followed by a Se-click reaction to conjugate the Bodipy593 fluorophore on calmodulin (CaM) and β-arrestin-1 (βarr1).

View Article and Find Full Text PDF

One nucleotide substitution in codon 90 of HLA-A*11:01:01:01 results in a novel allele, HLA-A*11:399.

View Article and Find Full Text PDF

The novel KIR3DL1*00702 allele differs from the closest allele KIR3DL1*00701 by a single silent mutation.

View Article and Find Full Text PDF
Article Synopsis
  • - The KIR2DS2*022 allele is a variant of the KIR2DS2 gene.
  • - It only differs from the KIR2DS2*00101 allele by one specific genetic mutation.
  • - This mutation is classified as nonsynonymous, meaning it alters the amino acid sequence of the protein produced by the gene.
View Article and Find Full Text PDF

One nucleotide substitution in codon 189 of HLA-C*01:02:01:01 results in a novel allele, HLA-C*01:179.

View Article and Find Full Text PDF

A substitution in exon 2 resulted in the novel HLA-A*30:140 variant identified in a Chinese individual.

HLA

September 2021

Immunogenetic Laboratory, Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, China.

HLA-A*30:140 differs from HLA-A*30:01:01 by one nucleotide change in exon 2 at position 341 (C > A).

View Article and Find Full Text PDF

One nucleotide substitution in codon 73 of HLA-A*11:01:01:01 results in a novel allele, HLA-A*11:396.

View Article and Find Full Text PDF

The HLA-DPA1*02:33 allele differs from DPA1*02:02:02:04 by two nucleotide change in exon 4.

View Article and Find Full Text PDF

Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates.

Emerg Microbes Infect

December 2021

Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, People's Republic of China.

COVID-19 vaccines are being developed urgently worldwide. Here, we constructed two adenovirus vectored COVID-19 vaccine candidates of Sad23L-nCoV-S and Ad49L-nCoV-S carrying the full-length gene of SARS-CoV-2 spike protein. The immunogenicity of two vaccines was individually evaluated in mice.

View Article and Find Full Text PDF

Selenocysteine (Sec), a rare naturally proteinogenic amino acid, is the major form of essential trace element selenium in living organisms. Selenoproteins, with one or several Sec residues, are found in all three domains of life. Many selenoproteins play a role in critical cellular functions such as maintaining cell redox homeostasis.

View Article and Find Full Text PDF

Due to the low incidence of concurrent human immunodeficiency virus (HIV) and syphilis infection identified during the early phase, such as window period (WP), little is known about the clinical manifestations, diagnosis, and treatment efficacy at very early stages. One longitudinal study was conducted in a 42-year-old blood donor who was concurrently infected with syphilis and HIV. This blood donor was treated with a penicillin-based regimen and early antiretroviral therapy (ART).

View Article and Find Full Text PDF